
GEORGE J WAN, PHD, MPH

31 Keith Lane, Newtown, PA 18940; 314-330-9167; georgewan@outlook.com

EXECUTIVE PROFILE

- 25+ years in healthcare/pharmaceuticals in medical affairs, value and access leadership roles.
- Multiple operating company experience in US and global organizations leading evidence generation and value translation functions in biopharmaceuticals, drug-devices and consumer.
- Broad-based therapeutic area expertise in Critical Care, CV/Metabolism, Hematology/Oncology, Immunology, Infectious Diseases, Neuroscience, Rare Diseases, Women's Health/Urology.
- Medical Leadership: Strategy, Field-Medical, Investigator-Initiated Trials, Real-World Evidence.
- Clinical Development Leadership: Patient-focused/RWE approaches to inform drug development.
- Value and Access Leadership: Health Economics, Market Access, Pricing and Reimbursement.
- Extensive skills in product launches and building in-house and field-based evidence generation and translation teams to communicate product value to providers, payers, and policy-makers.
- Demonstrated track record of developing high performing teams, leading over 30 professionals.

KEY ACCOMPLISHMENTS / RESPONSIBILITIES

- Build out team to deliver industry-leading capabilities to optimize access to biopharmaceuticals and drug-devices (850+ payer interactions with multiple favorable coverage decisions, 170+ initiatives completed, 170+ publications with proactive materials, 40+ press releases).
- Completed Nitric Oxide Treatment In COVID-19 Evaluation study to assess real-world outcomes.
- Serving as a senior medical leader within the company reporting to Executive Leadership.
- Responsible to ensure that all medical and value evidence generation activities are aligned with the Company's strategic and tactical plans and to effectively interface between Scientific and Commercial functions to warrant that strategies are aligned with corporate priorities.
- Development of department vision and implementing novel medical, value and access strategies.
- Providing direction and leadership to headquarter-based value evidence generation therapeutic leads as well as the field team (Field-Medical/value evidence translation leads).
- Creation of the overarching medical and value evidence generation strategy across all therapeutic areas and for all global regions in which Company operates.
- Development of a strong interface with stakeholders in other corporate functions (Marketing, Market Access, Medical Affairs, Clinical Development, Regulatory Affairs, Communications).

PROFESSIONAL EXPERIENCE

Vice-President, Global Head of Health Economics and Outcomes Research (2015-Present)
Mallinckrodt Pharmaceuticals, Science and Technology, Medical Department, Hampton, NJ
- Worldwide head of in-house and field-based HEMA/HEOR/Real-World Evidence Analytics

- Build out and execute integrated strategic plan and lead all value evidence generation activities.
- Establish and implement long-term evidence generation plan for marketed products, pre-launch products and life-cycle management programs connected with company objectives.
- Deliver globally aligned, evidence generation plan with focus on Integrated Evidence Generation.
- Provide strategic input into brand plans, including medical affairs plan as well as identifying unmet patient needs and opportunities to enhance product launches and life cycle management.
- Drive publication and evidence dissemination strategy in collaboration with medical affairs, clinical development, commercial, market access and corporate communications.

Various positions of increasing responsibility from Senior Director to Vice-President (2003-2015)

Johnson & Johnson (Europe and US locations)

- Global market access leader (Hepatitis C and Emerging Diseases: Dengue, Marburg Ebola, Rabies)
 - Global immunology transition leader for market access (SIMPONI™ and REMICADE®)
 - Head of outcomes research/real-world evidence for Centocor (now Janssen Biotech, Inc.)
 - Head of in-house and field HEOR for Janssen, Ortho-McNeil Neurologics, McNeil Pediatrics
 - Head of field medical, investigator-initiated studies, HEOR for Consumer Specialty Pharmaceuticals
-
- Responsible for aligning goals of the function with broader objectives of the global organization which includes partnering with commercial, development, regulatory and other key functions.
 - Collaborated across a matrix organization to create and execute an integrated evidence plan, which includes company sponsored and real-world evidence generation strategy to address existing and future data gaps, investigator-initiated research strategy aligned with brand plan.
 - Delivered scientific input into overall medical strategy and product launches, including evidence generation, communications and execution thereof to maximize access and commercial goals.
 - Provided leadership to Field-Medical organization, including medical science/managed markets/HEOR Liaisons to meet all medical affairs goals and key performance indicators.
 - Oversaw review, approval and alignment of investigator-initiated research and other evidence generation including outcomes research, to ensure execution within company standards.

Director, Global Health Outcomes Assessment promoted from Associate Director (2000-2003)

Wyeth (now Pfizer), Clinical Research and Development, Saint Davids, Pennsylvania

- Created health economic plans for products in oncology, neuroscience, and internal medicine.
- Led initiatives to identify and incorporate health economic endpoints for promotional claims, company-directed educational programs, and scientific communications.
- Developed the first Wyeth FDAMA 114 visual aid for use by account management with payers.
- Managed preparation of health economic-value dossiers for payer reimbursement.

Manager, Outcomes Research and Management (1997-2000)

Merck & Company, Inc., US Medical and Scientific Affairs, West Point, Pennsylvania

- Designed and executed large prospective outcomes studies in cardiovascular disease/diabetes.
- Created one of the first Merck FDAMA 114 payer tools for use with formulary decision-makers.
- Partnered with payer customers on disease management and quality improvement programs.

Consultant, BJC Health System, Center for Quality Management, Saint Louis, Missouri (1995-1997)

Research Analyst, Virginia Health Quality Center (Medicare QIO), Richmond, Virginia (1993-1994)

EDUCATION

PhD, Health Services Research/Epidemiology, Saint Louis University, Missouri, 1997

MPH, Virginia Commonwealth University, Richmond, Virginia, 1993

BA, Economics/Political Science, University of Richmond, Virginia, 1992

CLINICAL TRAINING

EMT – Basic (MO B-41223EMT), 1999-2000; (MO A-11670EMT), 1995-1998

National Registry of Emergency Medical Technicians – (B1061715), 1995-1998

ACADEMIC AND OTHER APPOINTMENTS

Corresponding Officer/Research Working Group, National Pharmaceutical Council, 2017-present
Corporate Member, Pharmacy Quality Alliance, Medication Adherence Workgroup, 2011
Member, National Quality Forum, Mental Health Outcomes Committee, 2009-2010
Member, Board of Visitors, Saint Louis University School of Public Health, 2008-2010
Associate, Johns Hopkins, Bloomberg School of Public Health, 2001-2002
Adjunct Faculty, Temple, Fox School of Business and Management, 1997-1999

HONORS

Predictive Diagnosis of Infantile Spasms, Patent Pending (62/873080) [Link](#)
Mallinckrodt CEO and CCO Achievement Awards, 2019, 2021
Thirty Mallinckrodt Impact Awards, 2017, 2018, 2019, 2020, 2021, 2022
Janssen Biotech President's Circle Award, 2012
Four Johnson & Johnson Standards of Leadership Awards, 2003, 2004, 2010, 2011
Ten Johnson & Johnson Encore Awards, 2006, 2008, 2010, 2011, 2014
Wyeth Above and Beyond Award, 2003; Wyeth Team of the Year Award, 2001
Merck & Company, Inc. Award of Excellence, 2000

SUMMARY OF PUBLICATIONS

Over seventy manuscripts published in medical specialty and managed care journals and one-hundred sixty presentations at scientific meetings.

MANUSCRIPTS WITH PRESS RELEASE

Abman SH, Fox NR, Malik I, Kelkar SS, Corman SL, Rege S, Bhaloo J, Shah R, Shei RJ, Saporito D, Shamseddine N, DeBoer E, Wan GJ. Real-world use of inhaled nitric oxide therapy in COVID-19 patients with mild to moderate acute respiratory distress syndrome. *Drugs in Context* 2022 (Apr.);11:2022-1-4. doi: 10.7573/dic.2022-1-4. [Link](#) [PR](#)

Busch H, Wan GJ, Niewoehner J, Houston P, Su Y, Clinton C, Panaccio MP. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis. *Drugs in Context* 2022 (Mar.);11:2021-10-4. doi: 10.7573/dic.2021-10-4. [Link](#) [PR](#)

Bindra J, Chopra I, Niewoehner J, Panaccio M, Wan GJ. Cost-effectiveness of repository corticotropin injection versus standard of care for the treatment of active rheumatoid arthritis. *ClinicoEconomics & Outcomes Research* 2021 (May); 13: 349-358. [Link](#) [PR](#)

Hayes K, Panaccio M, Houston P, Niewoehner J, Fahim M, Wan GJ, Dhillon B. Real-world treatment patterns and outcomes from an electronic medical records database for patients with rheumatoid arthritis treated with repository corticotropin injection. *Open Access Rheumatology: Research and Reviews* 2021 (Oct.); 13: 315-323. [Link](#) [PR](#)

Katz P, Wan GJ, Daly P, Topf L, Connolly-Strong E, Bostic R, Reed ML. Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus. *Quality of Life Research* 2020 (Jul.); 29(12): 3251-61. [Link](#) [PR](#)

Wan GJ, Chopra I, Niewoehner J, Hunter SF. Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis. *Drugs in Context* 2020 (Dec.); 9: 2020-9-4. DOI: 10.7573/dic.2020-9-4. [Link](#) [PR](#)

Chopra I, Qin Y, Kranyak J, Gallagher JR, Heap K, Carroll S, Wan GJ. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: Retrospective analysis of medical records. *Therapeutic Advances in Respiratory Disease* 2019 (Nov.); 13:1753466619888127. [Link](#) [PR](#)

Jamil K, Huang X, Lovelace B, Pham AT, Wan GJ. The burden of illness of hepatorenal syndrome in the United States: A retrospective analysis of EHRs. *JME* 2019 (May); 22(5): 421-429. [Link](#) [PR](#)

Urman RD, Böing EA, Khangulov V, Fain R, Nathanson BH, Wan GJ, Lovelace B, Pham AT, Cirillo J. Analysis of predictors of opioid-free analgesia for management of acute post-surgical pain in the US. *Current Medical Research & Opinion* 2019 (Feb.); 35(2): 283-289. [Link](#) [PR](#)

Hansen RN, Pham AT, Böing EA, Lovelace B, Wan GJ, Thomas DA, Fontes ML. Hospitalization costs and resource allocation in cholecystectomy with use of intravenous versus oral acetaminophen. *Current Medical Research and Opinion* 2018 (Sep.); 34(9): 1549-1555. [Link](#) [PR](#)

Shafi S, Collinsworth AW, Copeland LA, Ogola GO, Qui T, Kouznetsova M, Liao IC, Mears N, Pham AT, Wan GJ. Association of opioid-related AEs with clinical and cost outcomes among surgical patients in a large integrated health care delivery surgery. *JAMA Surgery* 2018 (Aug.); 153(8): 757-763. [Link](#) [PR](#)

Hansen RN, Pham A, Lovelace B, Balaban S, Wan GJ. Comparative analysis of inpatient costs for obstetrics and gynecology surgery patients treated with IV acetaminophen and IV opioids versus IV opioid-only analgesia for postoperative pain. *Ann Pharmacother* 2017 (Oct.); 51(10): 834-839. [Link](#) [PR](#)

Hansen RN, Pham AT, Böing EA, Lovelace B, Wan GJ, Miller TE. Comparative analysis of length of stay, hospitalization costs, opioid use, and discharge status among spine surgery patients with postoperative pain management including IV versus oral acetaminophen. *CMRO* 2017 (May); 33(5): 943-948. [Link](#) [PR](#)

Maiese BA, Pham A, Shah MV, Eaddy MT, Lunacsek OE, Wan GJ. Hospitalization costs for patients undergoing orthopedic surgery treated with intravenous acetaminophen (IV-APAP) plus other IV analgesics or IV opioid monotherapy for postop. pain. *Adv Ther* 2017 (Feb.); 34(2): 421-435. [Link](#) [PR](#)

Philbin M, Niewoehner J, Wan GJ. Clinical and economic evaluation of repository corticotropin injection: A narrative literature review of treatment efficacy and healthcare resource utilization for seven key indications. *Adv Ther* 2017 (Aug.); 34(8): 1775-1790. [Link](#) [PR](#)

Rice JB, White AG, Galebach P, Korenblat KM, Wagh A, Lovelace B, Wan GJ, Jamil K. The burden of hepatorenal syndrome among commercially-insured and Medicare patients in the United States. *Current Medical Research and Opinion* 2017 (Aug.); 33(8): 1473-1480. [Link](#) [PR](#)

Shaffer EE, Pham A, Woldman RL, Spiegelman A, Strassels SA, Wan GJ, Zimmerman T. Estimating the effect of intravenous acetaminophen for postoperative pain management on length of stay and inpatient hospital costs. *Adv Ther* 2017 (Jan.); 33(12): 2211-2228. [Link](#) [PR](#)

Hansen RN, Pham A, Strassels SA, Balaban S, Wan GJ. Comparative analysis of length of stay and inpatient costs for orthopedic surgery patients treated with intravenous (IV) acetaminophen and IV opioids versus IV opioids alone for postoperative pain. *Adv Ther* 2016 (Sep.); 33(9): 1635-1645. [Link](#) [PR](#)